AEYE is up +392.76% since Feb ’24 pick Unlock All Top Buy Picks
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of NGENF
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

NervGen Pharma Corp. stock price ended at $1.53 on Wednesday, after losing 0%.
(Updated on May 22, 2024)

Sell candidate since May 21, 2024 PDF

No changes to the price of NervGen Pharma Corp. stock on the last trading day (Wednesday, 22nd May 2024). During the last trading day the stock fluctuated 7.20% from a day low at $1.50 to a day high of $1.60. The price has been going up and down for this period, and there has been a 0.1% gain for the last 2 weeks.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -36.35% during the next 3 months and, with a 90% probability hold a price between $0.664 and $1.07 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

NGENF Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, April 17, 2024, and so far it has risen 6.88%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The NervGen Pharma Corp. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $1.55 and $1.55. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for NervGen Pharma Corp. stock

NervGen Pharma Corp. finds support from accumulated volume at $1.52 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.108 between high and low, or 7.20%. For the last week the stock has had daily average volatility of 8.56%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (NGENF) For The Upcoming Trading Day Of Thursday 23rd

For the upcoming trading day on Thursday, 23rd we expect NervGen Pharma Corp. to open at $1.54, and during the day (based on 14 day Average True Range), to move between $1.42 and $1.64, which gives a possible trading interval of +/-$0.105 (+/-6.87%) up or down from last closing price. If NervGen Pharma Corp. takes out the full calculated possible swing range there will be an estimated 13.74% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.52 (0.65%) than the resistance at $1.61 (5.23%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is NervGen Pharma Corp. stock A Buy?

NervGen Pharma Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -1.755 Sell Candidate Unchanged

Predicted Opening Price for NervGen Pharma Corp. of Thursday, May 23, 2024

Fair opening price May 23, 2024 Current price
$1.54 ( 0.82%) $1.53

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for NGENF

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.65 7.86 %
R2 1.61 5.17 %
R1 1.58 3.51 %
Current price: 1.53
Support S1 1.50 -1.87 %
S2 1.48 -3.53 %
S3 1.43 -6.22 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.67 9.15 %
R2 1.62 5.88 %
R1 1.61 5.23 %
Current price 1.53
Support S1 1.52 -0.654%
S2 1.50 -1.96%
S3 1.45 -5.23%

FAQ

What is the symbol for NervGen Pharma Corp. Stock and on which exchange is it traded?
The symbol for NervGen Pharma Corp. is NGENF and it is traded on the PINK (Pink Sheets).

Should I buy or sell NervGen Pharma Corp. Stock?
NervGen Pharma Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy NervGen Pharma Corp. Stock?
NervGen Pharma Corp. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy NervGen Pharma Corp. Stock.

What's the current price of NervGen Pharma Corp. Stock?
As of the end of day on the May 22, 2024, the price of an NervGen Pharma Corp. (NGENF) share was $1.53.

What is the 52-week high and low for NervGen Pharma Corp. Stock?
The 52-week high for NervGen Pharma Corp. Stock is $2.99 and the 52-week low is $1.16.

What is the market capitalization of NervGen Pharma Corp. Stock?
As of the May 22, 2024, the market capitalization of NervGen Pharma Corp. is 91.045M.

When is the next earnings date for NervGen Pharma Corp.?
The upcoming earnings date for NervGen Pharma Corp. is Aug 07, 2024.
Click to get the best stock tips daily for free!

About NervGen Pharma Corp.

NervGen Pharma . NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to resea... NGENF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT